Ailanthoidol, a Neolignan, Suppresses TGF-β1-Induced HepG2 Hepatoblastoma Cell Progression
Abstract
:1. Introduction
2. Materials and Methods
2.1. Materials
2.2. Cell Culture
2.3. Cytotoxicity Assay
2.4. Wound Healing Assay
2.5. In Vitro Cell Invasion Assay
2.6. Colony Assay
2.7. Preparation of Total Cell Extracts and Immunoblot Analysis
2.8. Statistical Analysis
3. Results
3.1. The Cytotoxicity of ATD on HepG2 Hepatoblastoma Cells
3.2. Inhibitory Effect of ATD on TGF-β1-Promoted Migration and Invasion of HepG2 Hepatoblastoma Cells
3.3. Effect of ATD on Colonization of HepG2 Hepatoblastoma Cells
3.4. Effect of ATD on TGF-β1-Induced Cell Scattering
3.5. Alterations of ATD on TGF-β1-Induced Progression Associated Protein Marker Expression in HepG2 Hepatoblastoma Cells
3.6. ATD Inactivating TGF-β1-Induced p38MAPK and SMAD Signaling
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bruix, J.; Gores, G.J.; Mazzaferro, V.M. Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut 2014, 63, 844–855. [Google Scholar] [CrossRef]
- Song, P.-M.; Zhang, Y.; He, Y.-F.; Bao, H.-M.; Luo, J.-H.; Liu, Y.-K.; Yang, P.-Y.; Chen, X. Bioinformatics analysis of metastasis-related proteins in hepatocellular carcinoma. World J. Gastroenterol. 2008, 14, 5816–5822. [Google Scholar] [CrossRef] [PubMed]
- Jiang, W.; Sanders, A.; Katoh, M.; Ungefroren, H.; Gieseler, F.; Prince, M.; Thompson, S.K.; Zollo, M.; Spano, D.; Dhawan, P.; et al. Tissue invasion and metastasis: Molecular, biological and clinical perspectives. Semin. Cancer Biol. 2015, 35, S244–S275. [Google Scholar] [CrossRef] [PubMed]
- Giannelli, G.; Koudelkova, P.; Dituri, F.; Mikulits, W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J. Hepatol. 2016, 65, 798–808. [Google Scholar] [CrossRef] [Green Version]
- Shankar, J.; Nabi, I.R. Actin Cytoskeleton Regulation of Epithelial Mesenchymal Transition in Metastatic Cancer Cells. PLoS ONE 2015, 10, e0119954. [Google Scholar] [CrossRef] [Green Version]
- Multhoff, G.; Molls, M.; Radons, J. Chronic Inflammation in Cancer Development. Front. Immunol. 2012, 2, 98. [Google Scholar] [CrossRef] [Green Version]
- Gupta, D.K.; Singh, N.; Sahu, D.K. Article Commentary: TGF-β Mediated Crosstalk between Malignant Hepatocyte and Tumor Microenvironment in Hepatocellular Carcinoma. Cancer Growth Metastasis 2014, 7, CGM.S14205–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Refolo, M.G.; Messa, C.; Guerra, V.; Carr, B.I.; D’Alessandro, R. Inflammatory Mechanisms of HCC Development. Cancers 2020, 12, 641. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peng, L.; Yuan, X.-Q.; Zhang, C.-Y.; Ye, F.; Zhou, H.-F.; Li, W.-L.; Liu, Z.-Y.; Zhang, Y.-Q.; Pan, X.; Li, G.-C. High TGF-β1 expression predicts poor disease prognosis in hepatocellular carcinoma patients. Oncotarget 2017, 8, 34387–34397. [Google Scholar] [CrossRef] [Green Version]
- Yu, L.; Hébert, M.C.; Zhang, Y. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 2002, 21, 3749–3759. [Google Scholar] [CrossRef] [Green Version]
- Durazzo, A.; Lucarini, M.; Camilli, E.; Marconi, S.; Gabrielli, P.; Lisciani, S.; Gambelli, L.; Aguzzi, A.; Novellino, E.; Santini, A.; et al. Dietary Lignans: Definition, Description and Research Trends in Databases Development. Molecules 2018, 23, 3251. [Google Scholar] [CrossRef] [Green Version]
- Teponno, R.B.; Kusari, S.; Spiteller, M. Recent advances in research on lignans and neolignans. Nat. Prod. Rep. 2016, 33, 1044–1092. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pan, J.-Y.; Chen, S.-L.; Yang, M.-H.; Wu, J.; Sinkkonen, J.; Zou, K. An update on lignans: Natural products and synthesis. Nat. Prod. Rep. 2009, 26, 1251–1292. [Google Scholar] [CrossRef] [PubMed]
- Peterson, J.; Dwyer, J.; Adlercreutz, H.; Scalbert, A.; Jacques, P.; McCullough, M.L. Dietary lignans: Physiology and potential for cardiovascular disease risk reduction. Nutr. Rev. 2010, 68, 571–603. [Google Scholar] [CrossRef] [Green Version]
- Barre, D.E.; Mizier-Barre, K.A. Lignans’ Potential in Pre and Post-onset Type 2 Diabetes Management. Curr. Diabetes Rev. 2019, 16, 2–11. [Google Scholar] [CrossRef]
- Ong, C.P.; Lee, W.L.; Tang, Y.-Q.; Yap, W.H. Honokiol: A Review of Its Anticancer Potential and Mechanisms. Cancers 2019, 12, 48. [Google Scholar] [CrossRef] [Green Version]
- Lee, Y.-J.; Kao, E.-S.; Chu, C.-Y.; Lin, W.-L.; Chiou, Y.-H.; Tseng, T.-H. Inhibitory effect of ailanthoidol on 12-O-tetradecanoyl-phorbol-13-acetate-induced tumor promotion in mouse skin. Oncol. Rep. 2006, 16, 921–927. [Google Scholar] [CrossRef]
- Kim, J.-K.; Jun, J.-G. Ailanthoidol suppresses lipopolysaccharide-stimulated inflammatory reactions in RAW264.7 cells and endotoxin shock in mice. J. Cell. Biochem. 2011, 112, 3816–3823. [Google Scholar] [CrossRef]
- Park, J.-H.; Jun, J.-G.; Kim, J.-K. Anti-Adipogenic Activity of Ailanthoidol on 3T3-L1 Adipocytes. Biomed. Sci. Lett. 2014, 20, 62–69. [Google Scholar]
- Lin, S.-Y.; Chen, C.-L.; Lee, Y.-J. Total Synthesis of Ailanthoidol and Precursor XH14 by Stille Coupling. J. Org. Chem. 2003, 68, 2968–2971. [Google Scholar] [CrossRef]
- Lee, H.; Pyo, M.J.; Bae, S.K.; Heo, Y.; Choudhary, I.; Hwang, D.; Yang, H.; Kim, J.-H.; Chae, J.; Han, C.H.; et al. Nemopilema nomurai jellyfish venom exerts an anti-metastatic effect by inhibiting Smad- and NF-κB-mediated epithelial–mesenchymal transition in HepG2 cells. Sci. Rep. 2018, 8, 2808. [Google Scholar] [CrossRef] [PubMed]
- Ganguly, K.K.; Pal, S.; Moulik, S.; Chatterjee, A. Integrins and metastasis. Cell Adhes. Migr. 2013, 7, 251–261. [Google Scholar] [CrossRef] [Green Version]
- Giannelli, G.; Fransvea, E.; Marinosci, F.; Bergamini, C.; Colucci, S.; Schiraldi, O.; Antonaci, S. Transforming Growth Factor-β1 Triggers Hepatocellular Carcinoma Invasiveness via α3β1 Integrin. Am. J. Pathol. 2002, 161, 183–193. [Google Scholar] [CrossRef]
- Hao, J.; Chen, D. TGF-β signaling in hepatocellular carcinoma suppression and progression. Tradit. Med. Res. 2018, 3, 10–21. [Google Scholar] [CrossRef]
- Koul, H.K.; Pal, M.; Koul, S. Role of p38 MAP Kinase Signal Transduction in Solid Tumors. Genes Cancer 2013, 4, 342–359. [Google Scholar] [CrossRef]
- Yu, L.-X.; Ling, Y.; Wang, H.-Y. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis. Oncol. 2018, 2, 6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Giannelli, G.; Villa, E.; Lahn, M. Transforming Growth Factor-β as a Therapeutic Target in Hepatocellular Carcinoma. Cancer Res. 2014, 74, 1890–1894. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, B.; Zhou, S.; Zhan, Y.; Ke, J.; Wang, K.; Liang, Q.; Hou, Y.; Zhu, P.; Ao, W.; Wei, X.; et al. Dioscin Inhibits the Invasion and Migration of Hepatocellular Carcinoma HepG2 Cells by Reversing TGF-β1-Induced Epithelial-Mesenchymal Transition. Molecules 2019, 24, 2222. [Google Scholar] [CrossRef] [Green Version]
- Yilmaz, M.; Christofori, G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009, 28, 15–33. [Google Scholar] [CrossRef] [Green Version]
- Samadani, A.A.; Norollahi, S.E.; Rashidy-Pour, A.; Mansour-Ghanaei, F.; Nemati, S.; Joukar, F.; Afshar, A.M.; Ghazanfari, S.; Safizadeh, M.; Rostami, P.; et al. Cancer signaling pathways with a therapeutic approach: An overview in epigenetic regulations of cancer stem cells. Biomed. Pharmacother. 2018, 108, 590–599. [Google Scholar] [CrossRef]
- Tu, S.; Huang, W.; Huang, C.; Luo, Z.; Yan, X. Contextual Regulation of TGF-β Signaling in Liver Cancer. Cells 2019, 8, 1235. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Luo, L.; Cai, L.; Luo, L.; Tang, Z.; Meng, X. Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells. Mol. Med. Rep. 2018, 17, 8053–8060. [Google Scholar] [CrossRef] [Green Version]
- Sano, Y.; Harada, J.; Tashiro, S.; Gotoh-Mandeville, R.; Maekawa, T.; Ishii, S. ATF-2 Is a Common Nuclear Target of Smad and TAK1 Pathways in Transforming Growth Factor-β Signaling. J. Biol. Chem. 1999, 274, 8949–8957. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Desai, A.; Qazi, G.; Ganju, R.; El-Tamer, M.; Singh, J.; Saxena, A.; Bedi, Y.; Taneja, S.; Bhat, H. Medicinal Plants and Cancer Chemoprevention. Curr. Drug Metab. 2008, 9, 581–591. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Amawi, H.; Ashby, J.C.R.; Samuel, T.; Peraman, R.; Tiwari, A.K. Polyphenolic Nutrients in Cancer Chemoprevention and Metastasis: Role of the Epithelial-to-Mesenchymal (EMT) Pathway. Nutrients 2017, 9, 911. [Google Scholar] [CrossRef] [Green Version]
- Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Rémésy, C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 2005, 81, 230S–242S. [Google Scholar] [CrossRef] [Green Version]
- Ranaware, A.M.; Banik, K.; Deshpande, V.; Padmavathi, G.; Roy, N.K.; Sethi, G.; Fan, L.; Kumar, A.P.; Kunnumakkara, A.B. Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer. Int. J. Mol. Sci. 2018, 19, 2362. [Google Scholar] [CrossRef] [Green Version]
- Leeson, P.D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 2007, 6, 881–890. [Google Scholar] [CrossRef]
- Ghanghas, P.; Jain, S.; Rana, C.; Sanyal, S. Chemopreventive action of non-steroidal anti-inflammatory drugs on the inflammatory pathways in colon cancer. Biomed. Pharmacother. 2016, 78, 239–247. [Google Scholar] [CrossRef] [PubMed]
- Khor, T.; Yu, S.; Kong, A.-N. Dietary Cancer Chemopreventive Agents—Targeting Inflammation and Nrf2 Signaling Pathway. Planta Medica 2008, 74, 1540–1547. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tseng, T.-H.; Lee, H.-J.; Lee, Y.-J.; Lee, K.-C.; Shen, C.-H.; Kuo, H.-C. Ailanthoidol, a Neolignan, Suppresses TGF-β1-Induced HepG2 Hepatoblastoma Cell Progression. Biomedicines 2021, 9, 1110. https://doi.org/10.3390/biomedicines9091110
Tseng T-H, Lee H-J, Lee Y-J, Lee K-C, Shen C-H, Kuo H-C. Ailanthoidol, a Neolignan, Suppresses TGF-β1-Induced HepG2 Hepatoblastoma Cell Progression. Biomedicines. 2021; 9(9):1110. https://doi.org/10.3390/biomedicines9091110
Chicago/Turabian StyleTseng, Tsui-Hwa, Huei-Jane Lee, Yean-Jang Lee, Ko-Chao Lee, Chien-Heng Shen, and Hsing-Chun Kuo. 2021. "Ailanthoidol, a Neolignan, Suppresses TGF-β1-Induced HepG2 Hepatoblastoma Cell Progression" Biomedicines 9, no. 9: 1110. https://doi.org/10.3390/biomedicines9091110